

## Detection of *csgA* gene in carbapenem-resistant *Acinetobacter baumannii* strains and targeting with *Ocimum sanctum* biocompounds

Saishree Anchana R<sup>1</sup>, Smiline Girija A.S.<sup>2\*</sup>, Shoba Gunasekaran<sup>3</sup>, Vijayashree Priyadharsini J<sup>4</sup>

<sup>1</sup> Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, P.H.Road, Chennai, Tamilnadu - 600077, India

<sup>2</sup> Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, P.H.Road, Chennai, Tamilnadu - 600077, India

<sup>3</sup> Department of Biotechnology, DG Vaishnav College, Arumbakkam, Chennai - 600 106

<sup>4</sup> Department of Microbiology & Blue Lab, [Instead of BRULAC-DRC] Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, P.H.Road, Chennai, Tamilnadu - 600077, India

### ARTICLE INFO

**Article type:**  
Original article

**Article history:**  
Received: Oct 16, 2020  
Accepted: Apr 17, 2021

**Keywords:**  
*Acinetobacter baumannii*  
Benzofuran  
Biofilms  
Drug resistance  
Eugenol  
*Ocimum sanctum*

### ABSTRACT

**Objective(s):** Carbapenem-resistant *Acinetobacter baumannii* (CRAB) is considered highly virulent due to *csgA* gene-mediated biofilm formation. The present study aimed to target the same gene, employing the antibiofilm effect of *Ocimum sanctum* (*O. sanctum*) essential oil compounds among CRAB strains.

**Materials and Methods:** A semi-quantitative adherent bioassay was performed to detect the biofilm formation in 73 CRAB strains. This was followed by molecular characterization, Polymerase Chain Reaction (PCR) amplification, and *csgA* gene sequencing. An antibiofilm assay under in vitro conditions, with essential oils of *O. sanctum* was performed. This was followed with further docking analysis of *csgA* protein with the selected compounds from the *O. sanctum* essential oils. A Molinspiration assessment was also done to elicit the drug likeliness of the biocompounds.

**Results:** The biofilm assay showed 58.9% as high-grade and 31.5% as low-grade biofilm formers, while 9.58% were non-biofilm formers. Molecular characterization of the *csgA* gene showed 20.54% (15/73) positivity. The strains that were imipenem resistant also showed the *csgA* gene to be present (100%; 15/15), with 60% (9/15) and 20% (3/15) for meropenem and doripenem resistance respectively. A crystal violet assay for determining cell viability was done in vitro, which gave Minimum biofilm inhibition concentrations of 50% (MBEC50) at 25  $\mu$ l and 90% (MBEC90) at 50  $\mu$ l. The docking analysis done *in silico* showed benzofuran to possess the lowest binding energy and highest hydrogen bond interactions.

**Conclusion:** The results indicate benzofuran, from the *O. sanctum* essential oils, to be effective in targeting the *csgA* gene among CRAB strains. Additionally, validation of these findings through *in vivo* studies is required.

### ► Please cite this article as:

Anchana RS, Girija ASS, Gunasekaran Sh, Priyadharsini JV. Detection of *csgA* gene in carbapenem-resistant *Acinetobacter baumannii* strains and targeting with *Ocimum sanctum* biocompounds. Iran J Basic Med Sci 2021; 24:690-698. doi: 10.22038/IJBMS.2021.52852.11917

### Introduction

*Acinetobacter baumannii*, a Gram-negative coccobacillus, is currently a major nosocomial pathogen (1) and its recent emergence (2), has marked it as one of the six most dangerous nosocomial pathogens by the World Health Organization (WHO) (3). It is a common inhabitant of soil, thus mistaken often as a soil pathogen (4). However, it is frequently isolated from hospital environments (5). Pneumonia, bacteremia, urinary tract infections, and meningitis are some commonly caused diseases by this opportunistic pathogen, among the immuno-compromised (6). The pathogen is also associated with clinical infections among patients in intensive care units (7). The pathogen's inherent resistance mechanisms and biofilm-forming capability make it multi-drug resistant (8). The exorbitant mortality rates in such diseases, is therefore, due to the multi-drug resistance of the pathogen, making it a herculean task to devise treatment strategies and control the progression of the diseases (9).

The *csgA* gene operon is exclusively associated with biofilm formation (10) facilitated by curli fibers (11), attributing to the organism's virulence (12). The curli fibers expressed by the *csgA* gene allow adhesion and invasion of *A. baumannii* to the epithelial cells of the host through extracellular matrix proteins (13). These fibers interact with the proteins and elicit an immune response in the host which further permit the organism to disseminate deeper into the tissues (14). Besides, they also slow down the activity of clotting factors (15), causing sepsis in the blood. This is noted by demonstration of *csgA* antibodies in the serum of sepsis patients (16).

Genomic and proteomic diversity of the *csgA* gene operon, that regulates curli expression has been analyzed in detail amidst Eubacteria (17). The presence of two subunits viz., *csgA* and *csgB* has been documented accordingly. Among these, the *csgA* subunit is the major subunit that assembles itself to form the cross-beta structures of the curli fibers (18). Meanwhile, the

\*Corresponding author: A.S. Smiline Girija. Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, P.H.Road, Chennai, Tamilnadu - 600077, India. Email: smilinejames25@gmail.com

*csgB* subunit, being the minor subunit, is responsible for specific nucleation of the *csgA* associated fibers in biofilms (19). The *csgA* mediated curli fibrils are resistant to chemical and proteolytic degradation, enabling *A. baumannii* to thrive in harsh environmental conditions. Co-occurrence of *A. baumannii* showing carbapenem resistance and the *csgA* gene has also been reported in earlier studies (20).

Hence, targeting the *csgA* gene might be an alternate method to confront drug-resistant strains of *A. baumannii*. Of the numerous natural herbs from India, *Ocimum sanctum* is believed to be the 'Queen of Herbs'. Phytochemical analysis found saponins, tannins, alkaloids, glycosides, and several medically significant compounds were present (21). In a previous study (22), many bio-compounds extracted from *O. sanctum* have been reported for their anti-bacterial, anti-inflammatory, and anti-oxidant nature (23). Hence, in the current study, the *csgA* gene present in multi-drug resistant *A. baumannii* was molecularly characterized, and the ligands estragole, eugenol, methyl eugenol, benzofuran, naphthalene, and citral from *O. sanctum*, were docked *in silico*, against the *csgA* gene.

## Materials and Methods

### Detection of biofilm formation using semi-quantitative adherence assay

Cells cultured in a flat-bottomed, microtiter plate with 96 wells, were assessed for biofilms produced by specifically drug-resistant strains, as done in a previous study (24). For each strain, the assay was done thrice, in trypticase soy broth (HiMedia, Mumbai, India) using 200 µl of the fresh broth culture, containing 0.25% of glucose (w/v). After incubating it with a negative control (broth + 0.25% glucose) and a positive control (an earlier detected *A. baumannii* strain that can form biofilm), for 24 hr at 37 °C, phosphate-buffered saline (PBS) was used to wash the plates for removing the free cells. Fixing adhered bacteria with 95% ethanol for 5 min was followed by drying the plates. Lastly, 100 µl of 1% w/v crystal violet solution (HiMedia) was used for staining the wells, with excess stains removed after a resting period of 5 mins using distilled water. The wells were dried and the measurement of optical density (OD) with a plate reader, at 570 nm (OD<sub>570</sub>) wavelength was done. The results of biofilm formation were graded accordingly into high (OD<sub>570</sub> greater than or equal to 1), low (0.1 less than or equal to OD<sub>570</sub> which is lesser than 1), or negative (OD<sub>570</sub> less than 0.1) values (25).

### Genomic DNA Extraction

A total of 73 strains of *A. baumannii* showing multi-drug resistance as used in our previous studies (26, 27) maintained at -80 °C in 80%/20% (v/v) glycerol from our repertoire, were retrieved in LB medium. All strains were cultured in Mac Conkey agar with incubation at 37 °C for 24 hr. The Qiagen DNA extraction kit was used for

genomic DNA extraction, which was done according to the instructions of the manufacturer, following which it was stored at 20 °C for future use.

### Detection of the *csgA* gene by PCR and sequencing

Detection of the *csgA* gene by PCR was achieved using primers (28) the PCR conditions are enlisted in Table 1. Genomic DNA was amplified using a programmable thermal cycler [Eppendorf Mastercycler, Germany]. Using ethidium bromide containing 1.5% agar gel, 15 µl of the PCR product was prepared at 90V in a Tris borate buffer for 40 min alongside an appropriate 1KB DNA ladder marker. The *csgA* amplicon products were bi-directionally sequenced from forward primers and reverse primers, using a BigDye Terminator Cycle Sequencing Kit, a Bio-edit sequence analyser, and a 3730XL Genetic analyser. Lastly, the sequences were subjected to a BLAST analysis for similarity search of the nucleotides and were aligned by default parameters for Multiple Sequence Alignment by the ClustalW software.

### Inhibitory effect of *O. sanctum* essential oils

#### Source of plant extract

Aerial parts of freshly cultivated *O. sanctum* plants were harvested, and essential oils were obtained by the hydro-distillation method. The extracted oil was dried to remove the excess water by adding anhydrous sodium sulfate. Following this, it was stored in dark vials at 4 °C.

#### Antibiofilm assay

A flat-bottomed, polystyrene microplate with 96 wells was used to assess the effect of *O. sanctum* essential oils on *A. baumannii* mediated biofilm formation as described earlier (29). In brief, *A. baumannii* that were *csgA* positive were prepared into suspensions, in sterile trypticase soy broth, and the 0.5 McFarland standard suspension was used. Control wells for comparison, with medium, organism, and oil suspensions were included. After incubating the plates for 24 hr at 37 °C, the supernatant was discarded and sterile distilled water was used to remove the free-floating cells. They were kept undisturbed for 30 min to allow air-drying. Once the wells were dry, an aqueous solution of 0.1% crystal violet was used for staining them; they were let to take up the stain for 15 min. The plates were washed thrice to remove the stains, with distilled water. As a final step, the wells were solubilized by adding 250 µl of ethanol, and a plate reader at 570 nm was used to measure the absorbance. The equation  $1 - (\text{Test}_{\text{OD570}} / \text{Control}_{\text{OD570}}) / 100$  gave the % of Inhibition. The concentrations showing 50% and 90% inhibition of the biofilm formed were determined as the minimum biofilm inhibition concentration (MBIC) (30).

#### *csgA* retrieval and optimization

The crystal structure of the gene of interest was obtained from the RCSB Protein Data Bank (<http://>

**Table 1.** Primer sequence and PCR conditions to detect *csgA* gene in MDR of *Acinetobacter baumannii* strains

Gene of target	Primer details	Annealing temp	Amplicon size
<i>csgA</i>	ATTTACCAGGATGGGCCGTG GCGCCACAACCAAGCAATTA	55	200 bp

www.rcsb.org/pdb) and was optimized by adding hydrogen atoms. The atoms of the proteins were assigned electronic charges and Kollman United Atoms Force-fields, with the help of the AutoDock Tool –1.5.6. The *csgA* gene's three-dimensional form was developed using the RasMol tool.

#### Preparation and optimization of ligands

The ChemsKetch software was used to visualize the structural configurations of the bio-active derivatives viz., estragole, eugenol, methyl eugenol, benzofuran, naphthalene, and citral from *O. sanctum*, which were drawn and generated as 3D structures. The ligands that were selected, were saved as MOL files, after which they were converted and saved in the PDB format, using the Open-label molecular converter program.

#### Molinspiration assessment for drug-likeness

Molecular descriptors including logP for partition co-efficient, the compounds' molecular weights, and the hydrogen bond acceptors' and donors' counts relating to their membrane permeability and bioavailability, were assessed by a Molinspiration assessment program (31). Further evaluations on absorption, distribution, metabolism, and elimination (ADME) exhibited by the ligands were assessed in lieu of the rule of five proposed by Lipinski (32).

#### Drug-ligand interactions by docking

The affinity between estragole, eugenol, methyleugenol, benzofuran, naphthalene, and citral, with the *csgA* gene of *A. baumannii*, was interpreted by docking, using the AutoDock tool. Using an auxiliary Autogrid program, the *csgA* protein was embedded in preset grid maps, one assigned each for a type of the atoms present in the compound that is being docked. The parameters of 12–10 and 12–6 given by Lennard–Jones, were applied to model all H-bonds and the van der Waals forces, respectively. The evaluation of the force field encompassed two steps viz., the intramolecular energetics from unbound states and bound conformations, and was given by the equation  $\Delta G = \Delta G_{vdw} + \Delta G_{hbond} + \Delta G_{elec} + \Delta G_{tor} + \Delta G_{desolv}$  (33).

#### Visualization of docking

The Discovery Studio Visualizer was used to visualize hydrogen bonds between estragole, eugenol, methyl eugenol, benzofuran, naphthalene, and citral, with the *csgA* gene of *A. baumannii*. Their molecular dynamics, affinity for binding, and energy simulation, besides further docking assessments, were used as parameters to assess their relative stabilities.

#### Statistical analysis

The obtained results were analyzed for statistical significance using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA). Fisher's exact 2-tailed test and Chi-square assessment were applied at  $P$ -value  $< 0.05$ . The frequency of the *csgA* gene among the CRAB strains was assessed using Pearson's correlation test.

## Results


### Correlating the *csgA* gene with CRAB strains

The biofilm assay among biofilm formers, indicated


43 strains (58.9%) under high grade, and 31.5% (23/73) under low grade, while 9.58% (7/73) did not form biofilm. Amidst the 43 strains showing high-grade biofilm-forming capability, all were imipenem resistant (100%; 43/43) followed by 76.7% (33/43) and 48.8% (21/43) for meropenem and doripenem resistance, respectively. Of the low-grade biofilm formers, all strains were resistant to imipenem, doripenem, and meropenem. The Pearson co-relation analysis yielded positive values suggesting the *csgA* gene to be occurring with CRAB strains ( $P$ -value  $< 0.05$ ). The molecular characterization of the gene, from the 73 genomes of CRAB strains, showed 20.54% (15/73) positive amplicons for the same (Figure 1). All strains resistant to imipenem showed the *csgA* gene to be present (100%; 15/15), followed subsequently by 60% (9/15) and 20% (3/15) resistant isolates against meropenem and doripenem, respectively.

### Antibiofilm assay results

The crystal violet assay for cell viability showed MBEC<sub>50</sub> at 25  $\mu$ l, indicating that *O. sanctum* essential oils showed 50% inhibition of the biofilms against *csgA* positive strains ( $P < 0.05$ ). Likewise, MBEC<sub>90</sub> was recorded at 50  $\mu$ l, showing 90% inhibition (Figure 2).



**Figure 1.** Electropherogram of *csgA* gene product of size 200 bp in lanes 1 and 2 with 1.5Kbp marker lane (M)



**Figure 2.** Graph showing the MBEC<sub>50</sub> and MBEC<sub>90</sub> values (OD<sub>600</sub> nm) of the crude *Ocimum sanctum* extracts against biofilm-forming *Acinetobacter baumannii*




Figure 3. *csgA* structure prediction by homology modeling using the Swiss-Model web server




Figure 4. Ramachandran plot for validation of the predicted structure using SAVES Server – PROCHECK

***csgA* Protein structure retrieval**

The FASTA sequence for the *csgA* gene present in *A. baumannii* was retrieved from the Uniprot database (sequence ID A0A335NTF8). Using the template 5WQO – A Chain, the structure of the *csgA* gene was modeled in the Swiss model server (Figure 3). The model showed 100% sequence identity compared with the template. Moreover, the Ramachandran plot indicated 95.9% of the residues to be in favored regions, with none in disallowed regions (Figure 4). The three-dimensional structure of the gene of interest was derived using



Figure 5. RasMol 3D structure of the *csgA* protein

RasMol in which the pink shade stands for alpha-helix, the yellow arrow denotes the beta sheets and the white shade denotes each turn (Figure 5).

**Retrieving the ligand- *O. sanctum* essential oils structures**

Optimization of the ligands was done using ACD Chemschetch software and the Open Babel Molecular Converter tool was used to convert them into a suitable format. Their two and three-dimensional structures and their SMILES format are shown in Figures 7 and 8.

**Drug likeliness parameter assessments**

Predictions of the bioactivity of estragole, eugenol, methyl eugenol, benzofuran, naphthalene, and citral, with the *csgA* gene of *A. baumannii*, were inferred from

**Table 2.** Molinspiration assessments of *Ocimum sanctum* ligands

Bio-compounds	Mol. wt	H-Donor	H-Acceptor	miLogP	Rotatable bonds	nViolations	TPSA (Å)	Volume	N atoms
Estragole	148.21	0	1	2.82	3	0	9.23	154.12	11
Eugenol	164.20	1	2	2.10	3	0	29.46	162.14	12
Methyleugenol	18.47	0	2	2.41	0	0	18.47	179.67	13
Benzofuran	374.35	0	9	4.49	6	0	119.35	318.05	27
Naphthalene	220.36	0	1	4.66	1	0	17.07	238.11	16
Citral	152.24	0	1	3.65	4	0	17.07	169.74	11
Ceftazidime	546.59	4	13	-5.68	9	2	191.23	439.78	37

the findings of the set default parameters with predicted scores and tabulated in Table 2. Benzofuran was observed to be the most capable candidate as a drug. Following it was eugenol, as the second most capable of targeting the *csgA* gene.

#### Docking analysis of *O. sanctum* derivatives against the *csgA* gene of *A. baumannii*

Based on the ligand-receptor structures amongst those that were docked, as well as the lowest energy, and the minimal solvent accessibility, the most suitable conformers were chosen with the aid of the Lamarckian Genetic Algorithm (LGA). The ball and stick models of hydrogen bond interactions in estragole, eugenol,

methyl eugenol, naphthalene, benzofuran, citral and the control, ceftazidime, against the *csgA* gene of *A. baumannii* were visualized using Acceryls Discovery Studio. These are given in Figure 4. The number of hydrogen bonds formed in concert with the torsional energy and the scores after the docking between the drug and ligands are also given in Table 3.

#### Overall docking energies and interactions

The binding energy together with other specific energies formed upon the interactions are shown in Table 4, with the energies reported in kcal/mol. The relative affinities of binding and the structure inhibitory activities for the *csgA* gene with estragole, eugenol,

**Table 3.** Interactions of ligands derived from *Ocimum sanctum* essential oils with *csgA* protein

S. No	Bio-active compound	csgA		Atom in bio-active compound	Distance (Å)	Docking energy (Kcal/Mol)
		Residue	Atom			
1.	Estragole	VAL184	N	O	2.92	-4.71
2.	Eugenol	TYR151	OH	O	3.04	-5.16
		SER135	OG	O	2.82	
		SER135	OG	O	2.50	
		SER135	OG	H	1.75	
3.	Methyleugenol	LEU59	N	O	3.01	-5.02
		LEU59	N	O	3.05	
4.	Benzofuran	ARG33	NH2	O	3.12	-9.27
		LYS155	NZ	O	2.66	
		ASN83	ND2	O	2.83	
		GLY14	N	O	2.97	
		ILE13	N	O	3.07	
		ILE13	N	O	2.85	
5.	Naphthalene	VAL184	N	O	2.75	-7.6
6.	Citral	ASN83	ND2	O	2.89	-4.87
		GLY14	N	O	2.93	
		ILE13	N	O	2.78	
7.	Ceftazidime	ARG33	NH2	O	2.97	-9.94
		ARG33	NE	O	2.92	
		ARG11	NH2	O	3.06	
		TYR151	OH	O	3.07	
		LYS155	NZ	O	2.88	
		GLY85	O	H	2.03	
		GLY85	N	O	2.78	

**Table 4.** Interaction scores of *Ocimum sanctum* against *csgA* of *Acinetobacter baumannii*


Compounds	Number of h-bonds	Binding energy	Ligand efficiency	Intermolecular energy	vdW + Hbond + desolv energy	Electrostatic energy	Torsional energy	Total internal unbound
Estragole	1	-4.71	-0.43	-5.61	-5.57	-0.04	0.89	-0.21
Eugenol	4	-5.16	-0.43	-6.36	-6.25	-0.11	1.19	-0.73
Methyleugenol	2	-5.02	-0.39	-6.21	-6.24	0.03	1.19	-0.36
Benzofuran	6	-9.27	-0.34	-11.06	-9.53	-1.54	1.79	-0.77
Naphthalene	1	-7.6	-0.48	-7.9	-7.83	-0.07	0.3	-0.29
Citral	3	-4.87	-0.44	-6.06	-5.99	-0.07	1.19	-0.27
Ceftazidime	7	-9.94	-0.27	-13.22	-10.81	-2.41	3.28	-2.35

**Table 5.** *Ocimum sanctum* bio-compounds overall interactions with *csgA*

Bio-compounds	H-bonds interactions	vW interactions	$\pi$ - $\sigma$ / $\pi$ - $\pi$ / amide- $\pi$ stacked interactions	alkyl/ $\pi$ -alkyl interactions
Estragole	1	8	-	2
Eugenol	4	10	-	3
Methyleugenol	2	9	1	2
Benzofuran	6	12	-	4
Naphthalene	1	11	-	10
Citral	3	5	-	5
Ceftazidime	7	14	1	5

methyl eugenol, benzofuran, naphthalene, and citral present in *O. sanctum* essential oils was assessed using a computational algorithm for docking. Among the compounds, benzofuran showed the lowest free binding energy of  $-9.27$  Kcal/mol with 6 hydrogen bonds, followed by eugenol with a free binding energy of  $-5.16$  Kcal/mol and 4 hydrogen bonds. Citral and methyl eugenol showed three and two hydrogen bond interactions, respectively, with the binding energies of

$-4.87$  Kcal/mol and  $-5.02$  Kcal/mol, each. The remaining two compounds, estragole and naphthalene, showed free binding energies of  $-7.6$  Kcal/mol and  $-4.71$  Kcal/mol, respectively, with 1 hydrogen bond. Other interactions formed from the interactions are also recorded under Table 5. Hence, the bio-compounds in the essential oils of *O. sanctum* showed a good binding affinity with the *csgA* gene. The compound benzofuran was observed to be the best candidate, when compared with the others,

**Figure 6.** Docking visualization of *csgA* gene with A – Estragole, B – Eugenol, C – Methyleugenol, D – Benzofuran, E – Naphthalene, F – Citral, G – Ceftazidime

to target the *csgA* gene, showing the best docking scores with 12 and 4 van der Waals interactions and alkyl/ $\pi$ -alkyl interactions, respectively.

## Discussion

Biofilm formation in *A. baumannii* is exhibited as a progressive process, involving the adhesion of bacteria to a surface, micro-colony development, followed by biofilm formation and maturing, and detachment leading to further colonization (34). Amidst various biofilm-associated genes, the *csgA* gene-mediated curli fibrils (35) are specifically known to transform a cell from its planktonic or single-celled state to a colonized community or a biofilm system (36). This further attributes to the pathogenicity and virulence of the biofilm-forming *A. baumannii* bacteria (37). Therefore, the current investigation was undertaken for the molecular characterization of the *csgA* gene and highlight its correlation with *A. baumannii* strains showing multi-drug resistance. In addition to this, the study also aimed to throw light on how to curb the development of biofilms in *A. baumannii*, as an alternative strategy to combat the menace of its survival. To substantiate this, the study has incorporated assessments on the activity of essential oils from *O. sanctum* against biofilm formed by *A. baumannii* strains that are *csgA* positive.

Previous studies have demonstrated the incidence of the *csgA* gene in *A. baumannii*, with 63% in a genotypic detection in associated with the biofilm formation-based virulence (38). In view of this, the occurrence of 20.54% positive amplicons among the CRAB strains observed in this study hypothesize the role of the *csgA* gene in enhancing the resistance and virulence of the *A. baumannii* strains showing multi-drug resistance. In contrast to this, previous literature had documented the absence of the gene in multi-drug resistant strains, highlighting the role of other genes in biofilm development (39). It is inferred that the role of the biofilm produced by the *csgA* gene, might differ as it is expressed (40) and thus, a periodical screening would give insights regarding the gene's potential role in virulence (41).

The gold standard crystal violet staining, to assess the activity of the chosen essential oil compounds against biofilm, was employed for its cost-effectiveness and ability to give rapid and adaptable laboratory results (42). Essential oils of *Ocimum* sp., have already shown to exhibit a good antibiofilm activity, as recorded in previous literature (43,44), against drug-resistant strains of *Staphylococcus aureus* (45) and *Escherichia coli* (46). No study however, has vividly documented the same against MDR (multi-drug resistant) strains of the organism of interest in the current study. Hence, the present study throws light on the antibiofilm activity of *O. sanctum* essential oils with a high inhibitory effect on the formation of biofilm in *csgA* positive *A. baumannii* strains.

The present study also intended to target the *csgA* gene-mediated biofilm, using natural bioactive compounds, for which essential oil compounds from *O. sanctum* were selected. The herb *O. sanctum* is easily available in India and several of its phenolic compounds have been structurally characterized in detail (47). Moreover, various bio-activities of the plant have been

evaluated and reported earlier (48). It has also been observed that essential oils from *O. sanctum*, encompass potent hydrophobic bio-compounds which are highly suitable for nano-formulations (49). According to previous literature, essential oils from the extracts of *Tulsi* possess a promising antibacterial property (50), attributed to the presence of 71% eugenol, in their compositions (51). In view of this, *O. sanctum* and its potent bio-compounds were selected for the drug-ligand interactions.

Since characterization of essential oils from *O. sanctum* has already been extensively analyzed, this study concentrated on *in silico* evaluation of the six bioactive compounds chosen as per findings in previous literature (52). In accordance with this, *csgA* was efficiently targeted by an *in silico* docking analysis using computational bio-informatic tools and databases. Based on factors like pose and strength core (53), a suitable ligand-receptor complex was obtained. The Biovia system was used to identify the number of hydrogen bonds and the bonding energies to obtain the best fit, with a high score, for benzofuran. In comparison with the control ceftazidime, albeit of its best binding scores, the strains selected for the study were resistant to the drug and many studies do document the same. Thus, the present investigation suggests benzofuran as the best candidate of choice for an alternative therapeutic strategy against drug-resistant strains of *A. baumannii*. Benzofuran is considered as a potent bio-compound from *O. sanctum* with a minimum inhibitory concentration (MIC) value of 29.76–31.96  $\mu\text{mol/L}$  as observed in an earlier study, indicating a vital anti-microbial activity (54).

The Molinspiration assessments, based on the specific parameters, showed high drug likeliness of the chosen compounds from *O. sanctum*, against *A. baumannii* possessing the *csgA* gene. The topological polar surface area (TPSA), in view of the drug absorption and bio-availability, indicates smooth and efficient binding of the selected ligands to the *csgA* protein. It is known that a TPSA value, equal to 140 Å or higher, indicates less absorption and oral bioavailability of the drugs (55). However, for the selected compounds from *O. sanctum* in the present study, TPSA values were less than 140 Å. Thus, the possibility of these compounds being formulated as drugs is highlighted from this finding.

Docking analysis involved investigating the free binding energy ( $\Delta G$ ) to predict the ligand binding with the *csgA*. The LGA assessed the binding conformational landscape of estragole, eugenol, methyl eugenol, benzofuran, naphthalene, and citral with the *csgA* gene. The docking scores of the *csgA* with the selected ligands showed a prominent relationship between the energies of the affinity of binding, stability, and low docking scores. Accordingly, the inter-molecular energies, van der Waal's forces, and torsional energies were comparatively higher for benzofuran followed by eugenol. Thus, it has been theoretically demonstrated that benzofuran from *O. sanctum* exhibited the highest inhibitory activity against the *csgA* gene-mediated formation of biofilm among MDR *A. baumannii* strains.

## Conclusion

The tenacious pathogen, *A. baumannii*, can be

inhibited by targeting the biofilm mediating *csgA* gene. This further, can be effectuated by derivatives of the essential oils of a commonly available herb, *O. sanctum*. Among the six bio-compounds chosen for the study, benzofuran and eugenol have shown favorable results in lieu of the study. Their inhibitory effect on the *csgA* gene has been substantiated *in vitro*, by the results of the antibiofilm assay, docking analysis, and Molinspiration assessment. Suitable TPSA values have also indicated that they can be considered for drug development. Therefore, the study has thrown light on an alternative means to address the menace of the recently progressing nosocomial pathogen, the MDR strains of *A. baumannii*.

### Acknowledgment

None.

### Funding Source

Self-funded study.

### Conflicts of Interest

None to declare.

### References

- Gonzalez-Villoria AM, Valverde-Garduno V. Antibiotic-resistant *Acinetobacter baumannii* increasing success remains a challenge as a nosocomial pathogen. *J Pathogens* 2016; :1-11.
- Wang X, Qin LJ. A review on *Acinetobacter baumannii*. *J Acute Dis* 2019; 8:16-21.
- Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007; 5:939-951.
- McConnell MJ, Pérez-Ordóñez A, Pérez-Romero P, Valencia R, Lepe JA, Vázquez-Barba I, et al. Quantitative real-time PCR for detection of *Acinetobacter baumannii* colonization in the hospital environment. *J Clin Microbiol* 2012; 50:1412-1414.
- Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. *Science* 2003; 301:105-107.
- Priyadharsini JV, Girija AS, Paramasivam A. An insight into the emergence of *Acinetobacter baumannii* as an oro-dental pathogen and its drug resistance gene profile—an *in silico* approach. *Heliyon* 2018; 4:1-18.
- Smiline Girija AS. CLSI based antibiogram profile and the detection of MDR and XDR strains of *Acinetobacter baumannii* isolated from urine samples. *Med J Islam Repub Iran* 2019; 33:3-9.
- Blanco N, Harris AD, Rock C, Johnson JK, Pineles L, Bonomo RA, et al. Risk factors and outcomes associated with multidrug-resistant *Acinetobacter baumannii* upon intensive care unit admission. *Antimicrobial Agents Chemother* 2018; 62:1-7.
- Akrami F, Namvar AE. *Acinetobacter baumannii* as nosocomial pathogenic bacteria. *Mol Gen Microbiol Virol* 2019; 34:84-96.
- Kikuchi T, Mizunoe Y, Takade A, Naito S, Yoshida SI. Curli fibers are required for development of biofilm architecture in *Escherichia coli* K-12 and enhance bacterial adherence to human uroepithelial cells. *Microbiol Immunol* 2005; 49:875-884.
- Saleem HG, Seers CA, Sabri AN, Reynolds EC. Dental plaque bacteria with reduced susceptibility to chlorhexidine are multidrug resistant. *BMC Microbiol* 2016; 16:1-9.
- DeBenedictis EP, Ma D, Keten S. Structural predictions for curli amyloid fibril subunits CsgA and CsgB. *Rsc Adv* 2017; 7:48102-48112.
- Wu L, Wu L, Wang T, Zou Z, Jiang X, Yin Q, Chen S. Use of magnetic nanoparticles for the detection of multidrug-resistant *Acinetobacter baumannii*. *Nanosci Nanotechnol Lett* 2018; 10:1165-1171.
- Bian Z, Brauner A, Li Y, Normark S. Expression of and cytokine activation by *Eschevichia coli* curli fibers in human sepsis. *J Infect Dis* 2000; 181:602-612.
- Hammar MR, Arnqvist A, Bian Z, Olsén A, Normark S. Expression of two *csg* operons is required for production of fibronectin-and congo red-binding curli polymers in *Escherichia coli* K-12. *Mol Microbiol* 1995; 18:661-670.
- Kwon SO, Gho YS, Lee JC, Kim SI. Proteome analysis of outer membrane vesicles from a clinical *Acinetobacter baumannii* isolate. *FEMS Microbiol Lett* 2009; 297:150-156.
- De Gregorio E, Roscetto E, Lula VD, Martinucci M, Zarrilli R, Di Nocera PP, et al. Development of a real-time PCR assay for the rapid detection of *Acinetobacter baumannii* from whole blood samples. *New Microbiol* 2015; 38:251-257.
- Cevahir N, Demir M, Kaleli I, Gurbuz M, Tikvesli S. Evaluation of biofilm production, gelatinase activity, and mannose-resistant hemagglutination in *Acinetobacter baumannii* strains. *J Microbiol Immunol Infect* 2008; 41:513-518.
- Perov S, Lidor O, Salinas N, Golan N, Tayeb-Fligelman E, Deshmukh M, Willbold D, Landau M. Structural insights into curli CsgA cross- $\beta$  fibril architecture inspire repurposing of anti-amyloid compounds as antibiofilm agents. *PLoS Pathogens* 2019; 15:1-31.
- Robinson LS, Ashman EM, Hultgren SJ, Chapman MR. Secretion of curli fibre subunits is mediated by the outer membrane-localized CsgG protein. *Mol Microbiol* 2006; 59:870-881.
- Obara H, Aikawa N, Hasegawa N, Hori S, Ikeda Y, Kobayashi Y, et al. The role of a real-time PCR technology for rapid detection and identification of bacterial and fungal pathogens in whole-blood samples. *J Infect Chemother* 2011; 17:327-333.
- Thummeepak R, Kongthai P, Leungtongkam U, Sitthisak S. Distribution of virulence genes involved in biofilm formation in multi-drug resistant *Acinetobacter baumannii* clinical isolates. *Int Microbiol* 2016; 19:121-129.
- Baliga MS, Jimmy R, Thilakchand KR, Sunitha V, Bhat NR, Saldanha E, et al. *Ocimum sanctum* L. (holy basil or tulsi) and its phytochemicals in the prevention and treatment of cancer. *Nutr Cancer* 2013; 65:26-35.
- Zheljazkov VD, Cantrell CL, Tekwani B, Khan SI. Content, composition, and bioactivity of the essential oils of three basil genotypes as a function of harvesting. *J Agric Food Chem* 2008; 56:380-385.
- Bhattacharyya P, Bishayee A. *Ocimum sanctum* Linn.(tulsi): an ethnomedicinal plant for the prevention and treatment of cancer. *Anticancer Drugs* 2013; 24:659-666.
- Kouidhi B, Zmantar T, Hentati H, Bakhrouf A. Cell surface hydrophobicity, biofilm formation, adhesives properties and molecular detection of adhesins genes in *Staphylococcus aureus* associated to dental caries. *Microbial Pathog* 2010; 49:14-22.
- Avila-Novoa MG, Solís-Velázquez OA, Rangel-Lopez DE, González-Gómez JP, Guerrero-Medina PJ, Gutiérrez-Lomelí M. Biofilm formation and detection of fluoroquinolone-and carbapenem-resistant genes in multidrug-resistant *Acinetobacter baumannii*. *Can J Infect Dis Med Microbiol* 2019; :1-5.
- Girija AS S, Priyadharsini J V. Prevalence of Acb and non-Acb complex in elderly population with urinary tract infection (UTI). *Acta Clin Belg* 2019; 22:1-7.
- Smiline Girija AS, Vijayashree Priyadharsini J, Arumugam P. CLSI based antibiogram profile and the detection of MDR and XDR strains of *Acinetobacter baumannii* isolated from urine samples. *Med J Islam Repub Iran* 2019; 33:11-16.



30. Zeighami H, Valadkhani F, Shapouri R, Samadi E, Haghi F. Virulence characteristics of multidrug resistant biofilm forming *Acinetobacter baumannii* isolated from intensive care unit patients. *BMC Infect Dis* 2019; 19:1-9.
31. Stauder M, Papetti A, Mascherpa D, Schito AM, Gazzani G, Pruzzo C, et al. Antiadhesion and antibiofilm activities of high molecular weight coffee components against *Streptococcus mutans*. *J Agric Food Chem* 2010; 58:11662-11666.
32. Preuss HG, Echard B, Enig M, Brook I, Elliott TB. Minimum inhibitory concentrations of herbal essential oils and monolaurin for Gram-positive and Gram-negative bacteria. *Mol Cell Biochem* 2005; 272:29-34.
33. Tariq M, Sirajuddin M, Ali S, Khalid N, Tahir MN, Khan H, Ansari TM. Pharmacological investigations and Petra/Osiris/Molinspiration (POM) analyses of newly synthesized potentially bioactive organotin (IV) carboxylates. *J Photochem Photobiol B* 2016; 158:174-183.
34. Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. *Drug Discov Today Technol* 2004; 1:337-341.
35. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, et al. Charmm general force field: A force field for drug-like molecules compatible with the Charmm all-atom additive biological force fields. *J Comput Chem* 2010; 31:671-690.
36. Watnick P, Kolter R. Biofilm, city of microbes. *J Bacteriol* 2000; 182:2675-2679.
37. Espinal P, Marti S, Vila J. Effect of biofilm formation on the survival of *Acinetobacter baumannii* on dry surfaces. *J Hosp Infect* 2012; 80:56-60.
38. Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. *J Tradit Complement Med* 2014; 4:24-35.
39. Davis JS, McMillan M, Swaminathan A, Kelly JA, Piera KE, Baird RW, et al. A 16-year prospective study of community-onset bacteremic *Acinetobacter pneumonia*: low mortality with appropriate initial empirical antibiotic protocols. *Chest* 2014; 146:1038-1045.
40. Gualdi L, Tagliabue L, Landini P. Biofilm formation-gene expression relay system in *Escherichia coli*: modulation of  $\sigma$ S-dependent gene expression by the CsgD regulatory protein via  $\sigma$ S protein stabilization. *J Bacteriol* 2007; 189:8034-8043.
41. Al-Kadmy IM, Ali AN, Salman IM, Khazaal SS. Molecular characterization of *Acinetobacter baumannii* isolated from Iraqi hospital environment. *New Microbes New Infect* 2018; 21:51-7.
42. Choudhury SS, Bashyam L, Manthapuram N, Bitla P, Kollipara P, Tetali SD. *Ocimum sanctum* leaf extracts attenuate human monocytic (THP-1) cell activation. *J Ethnopharmacol* 2014; 154:148-155.
43. Lee JS, Choi CH, Kim JW, Lee JC. *Acinetobacter baumannii* outer membrane protein A induces dendritic cell death through mitochondrial targeting. *J Microbiol* 2010; 48:387-392.
44. Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH, et al. Outer membrane protein 38 of *Acinetobacter baumannii* localizes to the mitochondria and induces apoptosis of epithelial cells. *Cell Microbiol* 2005; 7:1127-1138.
45. Kalaivani R, Devi VJ, Umarani R, Periyannayagam K, Kumaraguru AK. Antimicrobial activity of some important medicinal plant oils against human pathogens. *J Biological Active Prod Nature* 2012; 2:30-37.
46. Mirdha BR, Naik SN, Mahapatra SC. Antimicrobial activities of essential oils obtained from fresh and dried leaves of *Ocimum sanctum* (L.) against enteric bacteria and yeast. *Int Symp Med Nutraceutic Plants* 756 2007; :267-270.
47. Dey R, De K, Mukherjee R, Ghosh S, Haldar J. Small antibacterial molecules highly active against drug-resistant *Staphylococcus aureus*. *Med Chem Comm.* 2019; 10:1907-1915.
48. Burton E, Yakandawala N, LoVetri K, Madhyastha MS. A microplate spectrofluorometric assay for bacterial biofilms. *J Ind Microbiol Biotechnol* 2007; 34:1-4.
49. Amin MN, Dewan SM, Noor W, Shahid-Ud-Daula AF. Characterization of chemical groups and determination of total phenolic content and *in-vitro* anti-oxidant Activities of ethanolic extract of *Ocimum sanctum* leaves growing in Bangladesh. *Eur J Exp Biol* 2013; 3:449-454.
50. Hussain EH, Jamil K, Rao M. Hypoglycaemic, hypolipidemic and anti-oxidant properties of tulsi (*Ocimum sanctum* Linn) on streptozotocin induced diabetes in rats. *Indian J Clin Biochem* 2001; 16:190-194.
51. Rao YS, Kotakadi VS, Prasad TN, Reddy AV, Gopal DS. Green synthesis and spectral characterization of silver nanoparticles from Lakshmi tulasi (*Ocimum sanctum*) leaf extract. *Spectrochimica Acta A Mol Biomol Spectrosc* 2013; 103:156-159.
52. Jiang X, Liu W, Zhang W, Jiang F, Gao Z, Zhuang H, Fu L. Synthesis and antimicrobial evaluation of new benzofuran derivatives. *Eur J Med Chem* 2011; 46:3526-3530.
53. Barboza JN, da Silva Maia Bezerra Filho C, Silva RO, Medeiros JV, de Sousa DP. An overview on the anti-inflammatory potential and anti-oxidant profile of eugenol. *Oxid Med Cell Longev* 2018; :1-9.
54. Kenchappa R, Bodke YD, Asha B, Telkar S, Sindhe MA. Synthesis, antimicrobial, and anti-oxidant activity of benzofuran barbitone and benzofuran thiobarbitone derivatives. *Med Chem Res* 2014; 23:3065-3081.
55. Zhao Y, Sanner MF. FLIPDock: docking flexible ligands into flexible receptors. *Proteins Struct Funct Bioinf* 2007; 68:726-737.
56. Dhara L, Tripathi A. Antimicrobial activity of eugenol and cinnamaldehyde against extended spectrum beta lactamase producing *Enterobacteriaceae* by *in vitro* and molecular docking analysis. *Eur J Integr Med* 2013; 5:527-536.
57. Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules. *J Chem Inf Model* 2007; 47:460-463.